Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer

BackgroundProstate cancer represents a major health concern worldwide, with the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and locally advanced prostate cancer posing a particular challenge. Rezvilutamide, a new androgen receptor antagonist from China, has shown early promise;...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Chunlei Zhang, Jie Ren, Yindong Kang, Dehui Chang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Subjects:	prostate cancer rezvilutamide metastatic hormone-sensitive prostate cancer (mHSPC) androgen deprivation therapy (ADT) genetic testing
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1374039/full